Absci Corp (ABSI) - News Archive

In an era defined by rapid advancements in biotechnology, Absci Corporation is making significant strides that could alter the landscape of therapeutic development. At their recent 2024 Research and Development (R&D) Da...

Extensive Absci Announces Successful Closure of Public Offering of Common Stock, Boosting Investor Confidence and Funding for AI Drug CreationVANCOUVER, Wash., March 01, 2024 - Absci Corporation (Nasdaq: ABSI), a leadin...

In a recent press release, Absci Corporation (Nasdaq: ABSI), a pioneering data-first generative AI drug creation company, has announced its intention to launch an underwritten public offering of $75.0 million shares of...

Absci, a leading synthetic biology company, has recently announced significant progress in the development of ABS-101, a promising anti-TL1A antibody. The company is utilizing its innovative Generative AI technology to...

In a recent announcement that has caused waves in the medical research community, Absci Corporation revealed it will present preclinical data for its much-anticipated ABS-101, a potential best-in-class Anti-TL1A Antibod...

In a fascinating twist to the narrative of biotech in 2023, Absci, an AI biologics company, has announced a dynamic strategic Research and Development Partnership with PrecisionLife, a forerunner in precision medicine....

In an exciting development for the healthcare industry, Absci, a leading AI-driven biotechnology company, has announced a groundbreaking collaboration with AstraZeneca, a renowned pharmaceutical company. This collaborat...